Lantern Pharma (NASDAQ: LTRN), a clinical-stage, AI-driven precision oncology company, has received regulatory and Institutional Review Board (IRB) approvals in Taiwan to open Part 2 of its Phase 2 HARMONIC trial of LP-300. The lead Taiwan site is now open to accrual and actively screening patients, with the company anticipating IRB approval at two additional sites during the fourth quarter.
In the United States, a central IRB has approved the amended protocol, and clinical sites have begun identifying patients with the EGFR exon 21 L858R mutation. Part 2 will enroll patients with the L858R mutation who have progressed after tyrosine kinase inhibitor treatment. The amended protocol allows LP-300 to be administered for up to eight cycles in combination with carboplatin and pemetrexed, up from six cycles previously.
Preliminary data showed median progression-free survival of 8.9 months among nine L858R patients who completed six cycles, compared with 8.3 months among all 16 L858R patients evaluated. The company emphasized that these findings are preliminary, exploratory, and based on small patient numbers. For full details, see the complete press release.
The approvals mark a significant step for Lantern’s AI-driven approach to oncology drug development. The company leverages its proprietary RADR artificial intelligence and machine-learning platform to transform the cost, pace, and precision of oncology drug development. By integrating large-scale genomic and biological data with advanced machine learning, RADR is designed to identify the patients most likely to benefit from Lantern’s therapies and to guide biomarker-driven clinical development.
Lantern’s pipeline includes LP-184 (zirdafulven), LP-300, and LP-284, along with its central-nervous-system-focused subsidiary, Starlight Therapeutics, and its AI subsidiary, Open-Medicine AI. Investors can find the latest news and updates relating to LTRN in the company’s newsroom at https://ibn.fm/LTRN.
The news is being distributed through BioMedWire, a specialized communications platform focused on the biotechnology, biomedical sciences, and life sciences sectors. BioMedWire is part of the Dynamic Brand Portfolio at IBN, which offers access to a vast network of wire solutions via InvestorWire, article and editorial syndication to 5,000+ outlets, enhanced press release enhancement, social media distribution, and tailored corporate communications solutions.
For investors, the Taiwan approvals could accelerate patient enrollment and data readouts for LP-300, a potential treatment for a subset of lung cancer patients with limited options after progressing on tyrosine kinase inhibitors. The expansion to eight cycles may also provide deeper insights into the drug’s efficacy and safety profile. Lantern’s AI platform, if successful, could reduce the time and cost of bringing precision oncology therapies to market, an important consideration as the industry seeks more efficient development models. The company’s progress will be closely watched by stakeholders in the biotechnology sector.
